VC
Vivo Capital Portfolio holdings
AUM
$977M
This Quarter Return
+21.76%
1 Year Return
+209.68%
3 Year Return
+1,480.07%
5 Year Return
+2,591.98%
10 Year Return
–
AUM
$1.27B
AUM Growth
+$1.27B
(+4.2%)
Cap. Flow
-$84.7M
Cap. Flow
% of AUM
-6.66%
Top 10 Holdings %
Top 10 Hldgs %
71.44%
Holding
50
New
3
Increased
5
Reduced
8
Closed
8
Top Buys
| 1 |
SVA
Sinovac Biotech, Ltd
SVA
|
$76.3M |
| 2 |
Adverum Biotechnologies
ADVM
|
$21.2M |
| 3 |
Dyne Therapeutics
DYN
|
$17M |
| 4 |
RGLS
Regulus Therapeutics
RGLS
|
$14.4M |
| 5 |
SLN
Silence Therapeutics
SLN
|
$12.9M |
Top Sells
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Soleno Therapeutics
SLNO
$3.6B
| $360M | 28.31% | 8,418,093 | – | – |
|
2
Geron
GERN
$893M
| $89.8M | 7.06% | 27,225,292 +3,081,611 | +13% | +$10.2M |
|
3
Harmony Biosciences
HRMY
$2.12B
| $87.5M | 6.88% | 2,606,247 | – | – |
|
|
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
| $76.3M | 6% | +11,800,000 | New | +$76.3M |
|
|
AVDL
5
Avadel Pharmaceuticals
AVDL
$1.43B
| $67.1M | 5.27% | 3,972,099 -124,329 | -3% | -$2.1M |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $58.1M | 4.56% | 3,610,177 -639,741 | -15% | -$10.3M |
|
7
ALX Oncology
ALXO
$62.7M
| $47.1M | 3.7% | 4,220,048 | – | – |
|
|
8
Dyne Therapeutics
DYN
$1.92B
| $46.4M | 3.65% | 1,635,136 +600,000 | +58% | +$17M |
|
9
Terns Pharmaceuticals
TERN
$609M
| $43.7M | 3.43% | 6,657,992 | – | – |
|
10
Astria Therapeutics
ATXS
$349M
| $32.8M | 2.58% | 2,329,027 -153,700 | -6% | -$2.16M |
|
11
Viridian Therapeutics
VRDN
$1.5B
| $29.4M | 2.31% | 1,678,207 | – | – |
|
|
SLN
12
Silence Therapeutics
SLN
$227M
| $23.9M | 1.88% | 1,105,454 +595,250 | +117% | +$12.9M |
|
13
Olema Pharmaceuticals
OLMA
$375M
| $21.2M | 1.67% | 1,873,704 | – | – |
|
|
14
Adverum Biotechnologies
ADVM
$64.6M
| $21.2M | 1.67% | +1,500,000 | New | +$21.2M |
|
|
ALPN
15
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $20.8M | 1.63% | 520,505 -298,770 | -36% | -$11.9M |
|
16
Tarsus Pharmaceuticals
TARS
$2.47B
| $20.6M | 1.62% | 565,550 -1,218,456 | -68% | -$44.3M |
|
17
Verastem
VSTM
$569M
| $18.2M | 1.43% | 1,538,461 | – | – |
|
18
Crinetics Pharmaceuticals
CRNX
$2.92B
| $16.4M | 1.29% | 350,000 | – | – |
|
19
Cogent Biosciences
COGT
$1.69B
| $15.1M | 1.19% | 2,244,941 | – | – |
|
20
Sera Prognostics
SERA
$123M
| $15M | 1.18% | 1,650,440 | – | – |
|
|
RGLS
21
DELISTED
Regulus Therapeutics
RGLS
| $14.4M | 1.13% | +5,000,000 | New | +$14.4M |
|
22
Tourmaline Bio
TRML
$601M
| $13.6M | 1.07% | 591,882 | – | – |
|
|
CMPS
23
Compass Pathways
CMPS
$424M
| $13.4M | 1.05% | 1,608,000 | – | – |
|
24
Oric Pharmaceuticals
ORIC
$994M
| $11.7M | 0.92% | 849,681 | – | – |
|
25
enGene Holdings
ENGN
$236M
| $11.5M | 0.9% | 678,705 | – | – |
|